Loading
There are two separate questions, how big the limb is and how much it affects the person, and they need different instruments. Limb volume is measured by tape, by water displacement or by a device that passes a small current through the tissue; the effect on living is measured by a questionnaire such as LYMQOL.
Lymphoedema is the clearest case on this front of a problem where the objective and the subjective measure diverge, and where which one is used changes who gets treated.
Measuring the limb. Serial circumference measurement with a tape at fixed intervals, converted to volume by a truncated cone formula, is the usual clinical method. Water displacement is more accurate and almost nobody does it. Perometry uses infrared beams to compute volume quickly and is mostly a research tool. Bioimpedance spectroscopy passes a small alternating current and reports a ratio reflecting extracellular fluid, which changes before a limb visibly swells.
That last point is the subject of the PREVENT trial, a large prospective randomised screening trial comparing bioimpedance spectroscopy against tape measurement as the trigger for early compression after breast cancer treatment. Its three-year report describes when lymphoedema developed across the screening arms. The honest reading of the published PREVENT literature is that bioimpedance triggers intervention earlier, and that whether this reduces chronic lymphoedema was contested in correspondence after the interim analysis, with the letter and the authors' response both published in the same journal. A reader should know the disagreement exists rather than be told the question is settled.
Measuring the person. LYMQOL is the lymphoedema-specific quality of life questionnaire, with separate arm and leg versions and four domains plus a global question. Its Swedish validation in 102 patients with limb lymphoedema after cancer treatment reported intraclass correlation coefficients of 0.53 to 0.87 for the arm version and 0.78 to 0.90 for the leg version, with Cronbach's alpha of 0.79 to 0.93 and 0.87 to 0.94 respectively. The same study found that the association between the perceived degree of lymphoedema and the LYMQOL domains was significant in all domains for the leg version but only in function and body image for the arm version, which is a useful warning: how swollen an arm looks and how much it troubles the person are not the same thing.
Other instruments in use include ULL-27 for upper limb lymphoedema and the Lymphoedema Life Impact Scale; many trials instead use the arm symptom items inside the EORTC breast module.
What the measurement misses. A volume threshold, commonly a 10 per cent difference between limbs, is a convention and not a biological boundary: a person below it can have symptoms and a person above it can have none. Nothing routinely measures the skin changes, the heaviness or the infection risk that often matter more than the number. And there is no agreed measure at all for truncal, breast, head and neck or genital lymphoedema, which is a real gap: the limbs are measurable and therefore studied, and the rest is neither.
Extracellular fluid accumulation can be detected by impedance before it is visible as volume; volume can be measured before it is reported as a symptom; and the symptom can exist without either. Measuring at all three levels is the only way to tell which of the three a treatment changed.
Query for this technology: (TITLE:"Measuring lymphoedema: tape, bioimpedance and the quality of life scales" OR ABSTRACT:"Measuring lymphoedema: tape, bioimpedance and the quality of life scales") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Measuring lymphoedema: tape, bioimpedance and the quality of life scales, not a curated reading list.
Shares BREAST-Q and the Q-portfolio: measuring what an operation left behind, What a difference has to be before a person would notice it, How recovery is measured: the questionnaires behind the numbers, Quality of life and the tags rejuvenation, survivorship, measurement, instruments.
Shares What a difference has to be before a person would notice it, How recovery is measured: the questionnaires behind the numbers, Quality of life, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, measurement, instruments.
Shares What a difference has to be before a person would notice it, How recovery is measured: the questionnaires behind the numbers, Quality of life, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship, measurement, instruments.
Shares What a difference has to be before a person would notice it, How recovery is measured: the questionnaires behind the numbers, Quality of life, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, measurement, instruments.
Shares What a difference has to be before a person would notice it, How recovery is measured: the questionnaires behind the numbers, Quality of life, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, measurement, instruments.
Shares How recovery is measured: the questionnaires behind the numbers, Quality of life, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, measurement, instruments.
Shares How recovery is measured: the questionnaires behind the numbers, Quality of life, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, measurement, instruments.
Shares How recovery is measured: the questionnaires behind the numbers, Quality of life, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship, measurement, instruments.